Modulation of dihydrofolate reductase gene expression in methotrexate-resistant human leukemia CCRF-CEM/E cells by antisense oligonucleotides

Anti-Cancer Drugs

Volumn 11, Issue 4, 2000, Pages 285-294

  Morganti, Maria ^a   Coronnello, Marcella ^a   Caciagli, Barbara ^a   Biondi, Cristina ^a   Quattrone, Alessandro ^a   Capaccioli, Sergio ^a   Mazzei, Teresita ^a   Mini, Enrico ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Antisense; DHFR mRNA; Flow cytometry; Methotrexate resistance; Oligodeoxynucleotides; Reverse transcription polymerase chain reaction

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DIHYDROFOLATE REDUCTASE; MESSENGER RNA; METHOTREXATE; NUCLEASE; TRIMETHYLAMMONIUM SALT DERIVATIVE;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG RESISTANCE; FLOW CYTOMETRY; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA TRANSLATION;

DNA PRIMERS; DRUG COMBINATIONS; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; LEUKEMIA; METHOTREXATE; OLIGONUCLEOTIDES, ANTISENSE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TETRAHYDROFOLATE DEHYDROGENASE; TUMOR CELLS, CULTURED;

EID: 0034130873     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200004000-00010     Document Type: Article

References (54)

1. 1. Chu E, Allegra JC. Antifolates. In: Chabner BA, Longo DL, eds. Cancer chemotherapy and biotherapy: principles and practice. Philadelphia, PA: Lippincott-Raven 1996: 109-48.
2. 2. Bertino JR. Karnofsky memorial lecture. Ode to methotrexate. J Clin Oncol 1993; 11: 5-14.
3. 3. Dixon KH, Lanpher BC, Chiu J, Kelley K, Cowan KH. A novel cDNA restores reduced folate carrier activity and methotrexate sensitivity to transport deficient cells. J Biol Chem 1994; 269: 17-20.
4. 4. Ross JF, Prabir BS, Chaudhury K, Ratnam M. Differential regulation of folate receptor isoform in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 1994; 73: 2432-43.
5. 5. McGuire JJ, Mini E, Hsieh P, Bertino JR. Role of methotrexate polyglutamates in methotrexate-and sequential methotrexate-5-fluorouracil-mediated cell kill. Cancer Res 1985; 45: 6395-400.
6. 6. Dedhar S, Hartley D, Fitz-Gibbons D, Phillips G, Goldie JH. Heterogeneity in the specific activity and methotrexate sensitivity of dihydrofolate reductase from blast cells of acute myelogenous leukemia patients. J Clin Oncol 1985; 3: 1545-52.
7. 7. Göker E, Lin JT, Trippett T, et al. Decreased polyglutamylation of a methotrexate in acute lymphoblastic leukemia blast in adults compared to children with this disease. Leukemia 1993; 7: 1000-4.
8. 8. Saikawa Y, Knight CB, Saikawa T, Page ST, Chabner BA, Elwood PC. Decreased expression of the human folate receptor mediates transport defective methotrexate resistance in KB cells. J Biol Chem 1993; 268: 5293-301.
9. 9. Rhee MS, Wang Y, Nair MG, Galivan J. Acquisition of resistance to antifolates caused by enhanced γ-glutamyl hydrolase activity. Cancer Res 1993; 53: 2227-30.
10. 10. Masson E, Relling MV, Synold TW, et al. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. J Clin Invest 1996; 97: 73-80.
11. 11. Gorlick R, Göker E, Trippett T, et al. Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folale carrier expression. Blood 1997; 89: 1013-8.
12. 12. Carman MD, Schornagel JH, Rivest RS, et al. Resistance to methotrexate due to gene amplification in patient with acute leukemia. J Clin Oncol 1984; 2: 16-20.
13. 13. Horns Jr RC, Dower WJ, Schimke RT. Gene amplificaton in a leukemic patient treated with methotrexate. J Clin Oncol 1984; 2: 2-7.
14. 14. Trent JM, Buick RN, Olson S, Horns Jr RC, Schimke RT. Cytologic evidence for gene amplification in methotrexate-resistant cells obtained from a patient with ovarian adenocarcinoma. J Clin Oncol 1984; 2: 8-15.
15. 15. Göker E, Waltham M, Kheradpour A, et al. Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 gene mutations. Blood 1995; 86: 677-84.
16. 16. Matherly LH, Taub JW, Wong SC, et al. Increased frequency of expression of elevated dihydrofolate reductase in T-cell versus B-precursor acute lymphoblastic leukemia in children. Blood 1997; 90: 578-89.
17. 17 Ho PT, Parkinson DR. Antisense oligonucleotides as therapeutics for malignant diseases. Semin Oncol 1997; 24: 187-202.
18. 18. Bishop MR, Iversen PL, Bayever E, et al. Phase I trial of an antisense oligonucleotide OL (1) p53 in hematologic malignancies. J Clin Oncol 1996; 14: 1320-6.
19. 19. Webb A, Cunningham D, Cotter F, et al. Bcl-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 1997; 349: 1137-41.
20. 20. de Fabritiis P, Petti MC, Montefusco E, et al. BCR-ABL antisense oligodeoxynucleotide in vitro purging and aulologous bone marrow transplantation for patienls wilh chronic myelogenous leukemia in advanced phase. Blood 1998; 91: 3156-62.
21. 21. Gewirtz AM, Sokol DL, Ratajczak MZ. Nucleic acid therapeutics: state of the art and future prospects. Blood 1998, 92: 712-36.
22. 22. Kuss B, Cotter F. Antisense-time to shoot the messenger. Ann Oncol 1999; 10: 495-503.
23. 23. Nemunaitis J, Holmlund JT, Kraynak M, et al. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer. J Clin Oncol 1999; 17: 3586-95.
24. 24. Quattrone A, Papucci L, Morganti M, et al. Inhibition of MDR1 gene expression by antimessenger oligonucleotides lowers multiple drug resistance. Oncol Res 1994; 6: 311-20.
25. 25. Bertram J, Palfner K, Killian M, et al. Reversal of multiple drug resistance in vitro by phosphorothioate oligonucleotides and ribozymes. Anti-Cancer Drugs 1995; 6: 124-34.
26. 26. Li X, Smyth AP, Barrett DJ, Ivy SP, von Hofe E. Sensitization of multidrug-resistant human leukemia cells with MDR-targeted antisense and inhibition of drug-mediated MDR1 induction. Leukemia 1997; 11: 950-7.
27. 27. Maher LJ III, Dolnick BJ. Specific hybridization arrest of dihydrofolate reductase mRNA in vitro using antisense RNA or antisense oligonucleotides. Arch Biochem Biophys 1987; 253: 214-2.
28. 28. Kobayashi H, Kim N, Halatsch ME, Ohnuma T. Specificity of ribozyme designed for mutated DHFR mRNA. Biochem Pharmacol 1994; 47: 1607-13.
29. 29. Blume SW, Gee JE, Shrestha K, Miller DM. Triple helix formation by purine-rich oligonucleotides targeted to the human dihydrofolate reductase promoter. Nucleic Acids Res 1992; 20: 1777-84.
30. 30. Gee JE, Blume S, Snyder RC, Ray R, Miller DM. Triplex formation prevents Sp1 binding to the dihydrofolate reductase promoter. J Biol Chem 1992; 267: 11163-7.
31. 31. Mini E, Srimatkandada S, Medina WD, Moroson BA, Carman MD, Bertino JR. Molecular and kariological analysis of methotrexate-resistant and -sensitive human leukemic CCRF-CEM cells. Cancer Res 1985; 45: 317-24.
32. 32. Masters JN, Attardi G. The nucleotide sequence of the cDNA coding for human dihydrofolic reductase. Gene 1983; 21: 59-63.
33. 33. Morelli S, Delia D, Capaccioli S, et al. The antisense bcl-2-IGH transcript is an optimal target for synthetic oligonucleotides. Proc Natl Acad Sci USA 1997; 94: 8150-5.
34. 34. Schmitz JC, Agrawal S, Chu E. Repression of human thymidylate synthase mRNA translation by antisense 2′-O-methyl oligoribonucleotides. Antisense Nucleic Acid Drug Dev 1998; 8: 371-8.
35. 35. Ju J, Kane SE, Lenz HJ, Danenberg KD, Chu E, Danenberg PV. Desensitization and sensitization of cells to fluoropyrimidines with different antisenses directed against thymidylate synthase messenger RNA. Clin Cancer Res 1998; 4: 2229-36.
36. 36. Capaccioli S, Di Pasquale G, Mini E, Mazzei T, Quattrone A. Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and in human serum. Biochem Biophys Res Commun 1993; 197: 818-25.
37. 37 Quattrone A, Papucci L, Schiavone N, Mini E, Capaccioli S. Intracellular enhancement of intact antisense oligonucleotide steady-state levels by cationic lipids. Anti-Cancer Drug Des 1994; 9: 549-53.
38. 38. Mini E, Moroson BA, Bertino JR. Cytotoxicity of floxuridine and 5-fluorouracil in human T-lymphoblast leukemia cells: enhancement by leucovorin. Cancer Treat Rep 1987; 71: 381-9.
39. 39. Jackson RC, Huennekens FM. Turnover of dihydrofolate reductase in rapidly dividing cells. Arch Biochem Biophys 1973; 154: 192-8.
40. 40. Horikoshi T, Danenberg KD, StadlbauerTHW. Quantitation of thymidylate synthase, dihydrofolate reductase and DT-diaphorase gene expression in human tumors using the polymerase chain reaction. Cancer Res 1992; 52: 108-16.
41. 41. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-9.
42. 42. Ng SY, Gunning P, Eddy R, et al. Evolution of the functional human β-actin gene and its multipseudogene family: conservation of noncoding regions and chromosomal dispersion of pseudogenes. Mol Cell Biol 1985; 5: 2720-32.
43. 43. Assaraf YG, Seamer LC, Schimke RT. Characterization by flow cytometry of fluorescein-methotrexate transport in Chinese hamster ovary cells. Cytometry 1989; 10: 50-5.
44. 44. Ian TV. Proof without prejudice: use of the Kolmogorov-Smirnow test for the analysis of histograms from flow systems and other sources. J Histochem Cytochem 1977; 25: 935-41.
45. 45. Tidd DM. Ribonuclease H-mediated antisense effects in intact human leukemic cells. Biochem Soc Trans 1996; 24: 619-23.
46. 46. Pierga JY, Magdelenat H. Applications of antisense oligonucleotides in oncology. Cell Mol Biol 1994; 40: 237-61.
47. 47. Li XK, Kobayashi H, Holland JF, Ohnuma T. Expression of dihydrofolate reductase and multidrug resistance genes in trimetrexate resistant human leukemia cell lines. Leuk Res 1993; 17: 483-90.
48. 48. Cucco C, Calabretta B. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides. Cancer Res 1996; 56: 4332-7.
49. 49. Geary RS, Leed JM, Fitchett J, et al. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-RAF-1 kinase expression. Drug Metab Disp 1997; 25: 1272-81.
50. 50. Phillips JA, Craig SJ, Bayley D, Christian RA, Geary R, Nicklin PL. Pharmacokinetics, metabolism, and elimination of 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration. Biochem Pharmacol 1997; 54: 657-68.
51. 51. Qian M, Chen SH, von Hofe E, Gallo JM. Pharmacokinetics and tissue distribution of a DNA-methyltransferase antisense (MT-AS) oligonucleotide and its catabolites in tumor-bearing nude mice. J Pharmacol Exp Ther 1997; 282: 663-70.
52. 52. Goldman ID, Matherly LH. Biochemical factors in the selectivity of leucovorin rescue: selective inhibition of leucovorin reactivation of dihydrofolate reductase and leucovorin utilization in purine and pyrimidine biosynthesis by methotrexate and dihydrofolate polyglutamates. NCI Monogr 1987; 5: 17-26.
53. 53. Uhlmann E, Ryte A, Peyman A. Studies on the mechanism of stabilization of partially phosphorothioated oligonucleotides against nucleolytic degradation. Antisense Nucleic Acid Drug Dev 1997; 7: 345-50.
54. 54. Taylor IW, Slowiaczek P, Francis PR, Tattersall MH. Biochemical and cell cycle perturbations in methotrexate-treated cells. Mol Pharmacol 1982; 21: 204-10.